Thermo Fisher Scientific and Samsung Electronics to Collaborate on Point-of-Care Diagnostic Solutions
To answer the healthcare industry’s demand for better point-of-care (POC) diagnostics, Thermo Fisher Scientific Inc. and Samsung Electronics Co., Ltd. have formed a strategic collaboration. The companies will jointly design, develop and market new POC solutions in key applications, such as the detection of sepsis, drugs of abuse and therapeutic drug monitoring as well as the detection of cardiac problems and women’s health conditions.
According to the National Institutes of Health (NIH), POC testing enables patient diagnoses in a physician’s office; an ambulance; anywhere in the field, including a home; or in a hospital. This facilitates more rapid diagnosis and treatment. In its “fact sheet,” the NIH writes: “Empowering clinicians to make decisions at the ‘point-of-care’ has the potential to significantly impact health care delivery and to address the challenges of health disparities.”
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
DeCODE Study Links Gene Variant to Risk of Breast Cancer
U.S. Food and Drug Administration (FDA) Approves Recombinant Protein Treatment for Tibia Fractures - Wyeth's rhBMP-2/ACS Offers Potential for Improved Fracture Healing

FundaMental Pharma launches with EUR 10 million in Seed financing to advance a First-in-Class neuroprotectant - "These inhibitors have the potential to revolutionize therapies for currently untreatable neurodegenerative diseases"
New fat graft procedure promises long-term results in breast reconstruction
FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients
Sygnature Discovery: New Bioscience Group Fully-Operational & Winning Projects
Arkansas_Department_of_Human_Services_v._Ahlborn

New active substance against parasites
Biovitrum and Syntonix begin phase I/IIa clinical trial of long-acting recombinant Factor IXFc for treatment of Hemophilia B

Intra-Automation GmbH - Grevenbroich, Germany
